Tamoxifen safety in cystic fibrosis without modulators
Part of Digestive system, Genetic & congenital, Lungs & breathing clinical trials.
This study tests whether tamoxifen (a medication used for breast cancer) is safe and tolerable for adults with cystic fibrosis who cannot take CFTR modulators. It is an early trial focusing on safety, but it may help open new treatment options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have cystic fibrosis and are at least 18 years old.
- You are not taking CFTR modulators (like Trikafta, Orkambi, or Symdeko) because your mutations are not eligible.
- Your lung function is between 40% and 90% of the expected value.
- You have been stable for at least 3 weeks, with no recent flare-ups or changes in your cystic fibrosis therapy.
- You can use reliable non-hormonal birth control during the study and for 2 months after (if sexually active).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether tamoxifen, a hormone-blocking pill, can prevent pancreatic cysts from turning into cancer in people who are not having surgery to remove the cyst right away.
This trial tests how well cystic fibrosis (CF) medicine works for you using an “n-of-1” approach, meaning you try treatments in a structured, repeated way to see what helps you most. It may help your care team choose the best option for your specific CF genetics and health status.
This study tests whether people with cystic fibrosis who are already on a triple combination CFTR modulator can stay on their treatment without interruptions or problems. It aims to make sure everyone gets the best, most consistent treatment for their CF.
This study tests new treatments for cystic fibrosis in people who cannot take or choose not to take current CFTR modulators. It aims to find better options for managing CF.
This study tests whether a special nutrition supplement can improve health in adults with cystic fibrosis and pancreatic insufficiency who are already on a modulator therapy. The goal is to see if the supplement helps with digestion and overall well-being.
This observational study looks at how taking (or not taking) estrogen affects bone health in women with cystic fibrosis (CF). If you may have low estrogen, it also explores whether estrogen levels and symptoms relate to bone density over time.
Hear when a new Cystic Fibrosis - Complete trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.